CNC
Centene Corporation
$63.68
▲ 4.4%Updated Today 7:15 PM ET
▲ Up 10.6% over the last 12 months
Market Cap
$30.13B
P/E
—
Forward P/E (est.)
—
ROE
-28.7%
Revenue Growth
17.0%
EPS Growth
—
Profit Margin
-3.3%
FCF Yield
11.3%
Debt / Equity
0.87x
ROIC
-15.0%
Interest Coverage
—
Current Ratio
1.12x
Dividend Yield
—
Implied Growth (rev. DCF)
-4.7%
Rating Score
43/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what CNC's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. CNC trades near $63.68, above its 50-day average ($53.27) and 200-day average ($41.89). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 54 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. CNC's is $2.62 (~4.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month CNC found buyers near $56.74 (support) and sellers near $66.55 (resistance); its 52-week range is $25.08–$66.55. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.2× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Centene Corporation (CNC) is a large-cap company in the Managed Health Care industry, part of the Health Care sector of the S&P 500, with a market value around $30.13B.
In its latest reported year it generated about $174.58B in revenue and posted a net loss of $6.67B.
Our model rates CNC Neutral (43/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
10.3%
Revenue moved from $117.98B in 2021 to $174.58B in 2025, a 10.3% compound annual growth rate. The most recent year grew a strong 17.0% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
8.1%
Operating Margin
-4.4%
Net Margin
-3.8%
ROE
-28.7%
Centene Corporation keeps about -3.3% of each sales dollar as net profit, with a 8.1% gross margin and -4.4% operating margin. Return on equity is -28.7% and return on invested capital about -15.0%. The company is currently unprofitable on a net basis.
Total Debt
$17.49B
Net Debt
-$3.77B
Net cash position
Net Debt / EBITDA
—
Debt / Equity
0.87x
Leverage: debt-to-equity is 0.9x, with a current ratio of 1.1x. That is a moderate, manageable debt load for most businesses. It carries roughly $17.49B of total debt against $21.26B of cash.
Operating CF
$5.09B
Free Cash Flow
$4.32B
FCF Margin
2.5%
In the latest year Centene Corporation produced about $5.09B of operating cash flow and $4.32B of free cash flow after capital spending. That is a free-cash-flow yield of about 11.3% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
—
P/S
0.15x
P/B
1.01x
EV / EBITDA
—
CNC trades at n/a trailing earnings, 0.2x sales, and 1.0x book value. Reverse-engineering today's price implies the market expects roughly -4.7% long-term free-cash-flow growth. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How CNC stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), CNC ranks #45 of 59 by our overall rating.
P/E vs sector
—
median 25.4x
ROE vs sector
-28.7%
median 14.9%
Growth vs sector
17.0%
median 7.9%
Sector rank
#45
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$279.05 – $465.08
vs. $63.68 today · expected CAGR 34% – 49%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $204.26B | $238.98B | $279.61B | $327.15B | $382.76B |
| Net income | $6.13B | $7.17B | $8.39B | $9.81B | $11.48B |
| EPS | $12.41 | $14.52 | $16.99 | $19.88 | $23.25 |
| Share price (low) | $148.91 | $174.23 | $203.85 | $238.50 | $279.05 |
| Share price (high) | $248.19 | $290.38 | $339.75 | $397.51 | $465.08 |
| CAGR (low–high) | 134% / 290% | 65% / 114% | 47% / 75% | 39% / 58% | 34% / 49% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for CNC:
- Revenue is growing 17.0% a year, a sign of real demand.
- Healthy free-cash-flow yield (~11.3%) funds buybacks and dividends.
The case against CNC:
- Thin net margins (-3.3%) leave little room for error.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Margin risk — thin profitability (-3.3%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Centene Corporation is a large-cap health care business still growing nicely, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Neutral (43/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.